Key Drivers
- Very high margins
- Negative free cash
- Rich valuation
AIAI Summary
Cohen & Steers should be reclassified from a steady-dividend, high-margin manager to a market- and flow-dependent growth story where the main investment risk is that materially negative free cash flow and an 83–91% payout make the dividend unsustainable unless operating cash flow turns positive or ETF/product conversions deliver durable net inflows—monitor next-quarter OCF, organic net flows (not just market appreciation), and any management capital-allocation actions as clear buy/sell triggers.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Very high margins
- •Negative free cash
- •Rich valuation
CNS combines exceptional margins and returns with conservative leverage and sizable liquid/invested assets, but persistent negative free cash flow from high dividends and rich multiples create material downside risk. #high-margins
Price Behavior
Key Price Behavior Insights:
- •Below SMA
- •RSI ~35
- •Support ~62
CNS is in a short-term downtrend, trading below its last month SMA (~$64.8) with RSI near 35 and near-term support around $62 (deeper ~$61.40) while resistance sits at $64.5–65 and in the mid–high $60s.
Price fell from $66.43 on 2026-02-20 to $62.18 on 2026-03-20, marking a clear short-term decline
Sentiment & News
Key News Insights:
- •Dividend declared
- •Mutual-to-ETF
- •Pipeline refocus
Cohen & Steers announced a $0.67 quarterly dividend, AUM growth and a mutual‑to‑ETF conversion for its Future of Energy fund amid institutional flows, while CNS Pharmaceuticals appointed a new CMO and shifted to a neurology/oncology pipeline as Corero earned market recognition.
These moves should support Cohen & Steers' fee growth and investor appeal in the near term, while CNS Pharmaceuticals' leadership and portfolio pivot aim to enhance biotech value creation
Similar Companies in Financial Services
Other companies in the same sector with AI ratings